Homeobox genes are known to be classic examples of the intimate relationship between embryogenesis and tumorigenesis, which are a family of transcriptional factors involved in determining cell identity during early development, and also dysregulated in many malignancies. Previously, HOXB7, HOXC6 and HOXC8 were found abnormally upregulated in esophageal squamous cell carcinoma (ESCC) tissues compared with normal mucosa and seen as poor prognostic predictors for ESCC patients, and were shown to promote cell proliferation and anti-apoptosis in 
| INTRODUC TI ON
Esophageal cancer is one of the most common cancers worldwide.
According to the global cancer statistics of 2012, each year an estimated 456 000 people are newly diagnosed with esophageal cancer, resulting in 400 000 deaths. 1 In China, the majority of cases are esophageal squamous cell carcinoma (ESCC), and most patients are diagnosed at a relatively advanced stage. Currently, the development of comprehensive perioperative therapies has greatly improved the efficacy of ESCC treatment, but the long-term survival remains poor because of recurrence and resistance commonly occurring. Therefore, it is urgent to explore novel actionable targets and develop effective new therapy.
It is common knowledge that there is some similarity between embryogenesis and carcinogenesis. During the last decade, dysregulated expression of HOX genes has been described in many solid tumors and derivative cell lines, 6, 7 and overexpression of HOX genes was associated with poor prognosis. [8] [9] [10] [11] [12] In our previous study, we found that 11 of 39
HOX genes were overexpressed in ESCC tissues compared with paired noncancerous mucosa, 13 including HOXB7, HOXC6 and HOXC8. Moreover, we showed that these HOX genes promoted oncogenic properties in ESCC cells and presented negative survival significance in ESCC patients. 14, 15 Specifically, knockdown of HOXB7, HOXC6 or HOXC8 resulted in antiproliferation and proapoptosis phenotype in ESCC cell lines, and induced cell cycle arrest in G1 phase, and inhibited tumor growth in a mice xenograft model.
HOX genes have distinct functions in a specific context during early development, and this functional complexity is also seen in tumorigenesis, with some HOX genes functioning as oncogenes and others as tumor suppressors. 6 Specific reasons for these opposing functions are still unclear, However, it may be related to different regulation of target genes. DNA binding selectivity of HOX proteins is mediated by a homeodomain together with a defined set of cofactors including the PBX, MEIS and PREP families. 16 Therefore, a high level of functional redundancy is seen among some HOX members, especially regarding the HOX genes localized in relative positions within the cluster. This is also true in ESCC, where a similar oncogenic function is common to HOXB7, HOXC6 and HOXC8. As a result of the functional redundancy, it is not only difficult to interpret the results of conventional knockdown results for single HOX genes, but it also makes targeting a single HOX gene very difficult.
Therefore, exploring a way to target multiple HOX genes could potentially be a better strategy to explore the oncogenic role of HOX members by disrupting the interaction of HOX proteins with their cofactors. PBX is the defined as a cofactor binding to HOX members 1-9 17 which modifies DNA binding specificity and affinity and regulates the nuclear-cytoplasm transport of HOX proteins. 18, 19 The interaction is mediated by a highly conserved hexapeptide region in HOX proteins. 18, 20 Previously, it was shown that a synthetic peptide known as HXR9 was capable of blocking the interaction between HOX and PBX proteins both in vitro and in vivo. HXR9
functioned as a competitive antagonist of the interaction by mimicking the conserved hexapeptide region. 21 The present study aimed to investigate whether HXR9 could block the interaction between multiple HOX members (HOXB7, HOXC6, HOXC8) and PBX in ESCC cells and inhibit their oncogenic functions. Moreover, we attempted to search for the potential target genes in response to HXR9 treatment, which may be the clue to the mechanism underlying the effect of HOX/PBX inhibition.
| MATERIAL S AND ME THODS

| Cell lines and cell culture
Human ESCC cell lines KYSE70, KYSE150, KYSE450 were pur- Incubator was maintained at 37°C humidified atmosphere containing 5% CO 2 .
| Synthesis of HXR9 and CXR9 peptides
The HOX/PBX interfering peptide HXR9 and control peptide (CXR9)
were custom synthesized by Sangon Biotech Co. Ltd (Shanghai, China), with >98% purity. The powdered peptides were dissolved in ddH 2 O to a final concentration of 20 mmol/L, and stored at −20°C.
HXR9 is an 18-amino acid peptide consisting of the hexapeptide sequence that can bind with PBX and nine C-terminal arginine residues (R9) that facilitate its entry into cells. CXR9 differs from HXR9 by a single amino acid so that it lacks a functional hexapeptide sequence but still includes the R9 sequence. Sequences of the peptides are as follows: HXR9: WYPWMKKHHRRRRRRRRR, CXR9:
WYPAMKKHHRRRRRRRRR. 
| CCK-8 assay
| Colony formation assay
Plated cells were treated with 60 μmol/L HXR9 or CXR9 for 8 hours prior to replating at 500 cells/well in six-well plates. Cells were maintained at 37°C and the completed medium was replaced by fresh one every 4 days for the following 2 weeks. Subsequently, obtained colonies were visualized by methanol fixation and 0.1% crystal violet staining. Number of colonies was counted in control, CXR9-treated and HXR9-treated groups from at least three independent experiments.
| Cell apoptosis analysis
Cells were plated at a density of 1 × 
| Western blotting
Cells were treated with 60 μmol/L HXR9 or CXR9 for 2 hours. Total proteins were extracted by using RIPA lysis buffer with protease Goat antirabbit IgG (ZB-2301 at 1:5000; ZSGB-BIO) and goat antimouse IgG (ZB-2305 at 1:5000; ZSGB-BIO) were used as the secondary antibodies.
| Immunofluorescent colocalization
Cells were plated at a density of 1 × 10 Immunofluorescence was visualized by Zeiss scanning microscope (Zeiss Germany, Oberkochen, Germany).
| Coimmunoprecipitation
Cells were treated with 60 μmol/L HXR9 or CXR9 for 2 hours and proteins were extracted by using cold immunoprecipitation (IP) lysis buffer (Thermo Fisher Scientific) with protease inhibitor cocktail and pre-cleared by Control Agarose Resin (26150; Thermo Fisher Scientific). The PBX antibody (sc-28313 at 20 μg/mL; Santa Cruz Biotechnology) was immobilized using AminoLink Plus Coupling
Resin (Thermo Fisher Scientific). Then the pre-cleared lysate was incubated in antibody immobilized resin with gentle mixing overnight at 4°C. After incubation, the resin was eluted using elution buffer (21004; Thermo Fisher Scientific). Samples of elution buffer were prepared for western blotting analysis as described above. for KYSE150, the mice were randomly divided into two groups and received an initial dose of 100 mg/kg CXR9 or HXR9 (i.v. or intratumor), respectively, followed by twice weekly treatments at 10 mg/ kg. Mice were monitored carefully; after 18 days, tumors were excised, and measured by a slide caliper for volume and weighed with an electronic analytical balance.
| Esophageal squamous cell carcinoma
| Immunohistochemistry
Nude mouse tumors were fixed in 4% formalin immediately after dissection. Subsequently, dehydration, transparency, soaking, and embedding were sequentially carried out, and tissues cut into 4-μm sections. After routine deparaffinization and hydration, tissue sections were treated with 3% hydrogen peroxide for 10 minutes and then heated in citrate solution for antigen retrieval for 5 minutes.
After antigen retrieval, the sections were incubated with 10% normal goat serum to block any nonspecific reaction and incubated in primary antibody dilutions overnight at 4°C. The primary antibodies used were anti-Caspase-3 (9662 at 1:1000; Cell Signaling, America), 
| RNA sequencing
Total RNA from KYSE70 and KYSE150 treated with HXR9 or CXR9
(60 μM) with three replications was isolated using Trizol for the construction of a RNA-seq library and sequencing. Details of RNA sequencing was described in our previous study. 
| Statistical analysis
| Targeting HOX/PBX interaction in ESCC cell lines (KYSE70, KYSE150, KYSE450)
Given PBX binding to HOX modifies the selection of DNA binding sites and the identity of HOX target genes, a short peptide HXR9
was designed in previous work to disrupt HOX/PBX dimer formation. This peptide mimics the 'hexapeptide' sequence in HOX proteins and penetrates cells efficiently. [23] [24] [25] [26] In the present study, we detected whether HXR9 could block HOX/PBX interaction in ESCC cells through coimmunoprecipitation and fluorescence colocalization assay. As a control, a second peptide CXR9 was used which lacks a functional hexapeptide portion.
As HOXB7, HOXC6, HOXC8 are known PBX-binding partners, to test the specificity of HXR9 to block PBX/HOX dimer formation, we treated ESCC cell lines KYSE70, KYSE150 and KYSE450
with 60 μmol/L HXR9 or CXR9 for 2 hours and total protein was extracted. PBX was then immunoprecipitated using a monoclonal anti-PBX antibody. Then the immunoprecipitation complex was F I G U R E 1 HXR9 disrupts HOX/PBX interaction in esophageal squamous cell carcinoma cells. KYSE70, KYSE150, KYSE450 were treated with 60 μmol/L HXR9 or CXR9 for 2 h. A, Protein was extracted and precipitated using anti-PBX antibody. Precipitates were subjected to western blotting using anti-HOXB7, anti-HOXC6 and anti-HOXC8. In HXR9-treated cells, the binding of PBX to HOX was abrogated. Densitometry quantification of HOXB7, HOXC6 and HOXC8 expression in coimmunoprecipitation (Co-IP) assay is presented. B, Cells were fixed and colabeled with anti-PBX and anti-HOXB7/anti-HOXC6/anti-HOXC8. PBX and HOX colocalization were analyzed by immunofluorescence microscopy. In HXR9-treated cells, HOX/PBX dimer formation decreased remarkably compared to control or CXR9-treated cells. Percentage of HOX/PBX colocalization foci is quantified. *P < 0.05, **P < 0.01 and ***P < 0.001 collected and subjected to western blotting using anti-HOXB7, anti- 
| HXR9 blocks the pro-proliferation function of HOXB7/HOXC6/HOXC8 in vitro and in vivo
We have mentioned that knock down of HOXB7/HOXC6/HOXC8
inhibited ESCC cell proliferation. In the present study, we wanted and KYSE150, respectively. On day 18, TGI of xenograft tumor was 59.3% and 65.0% for KYSE70 and KYSE150, respectively. However, body weight loss in mice treated with HXR9 was not significantly greater than that in mice treated with CXR9, indicating that HXR9
had no overt toxicity to mice.
| HXR9 induces apoptosis in ESCC cells in vitro and in vivo
In order to establish whether HXR9 induces apoptosis, HXR9-or for KYSE70 and 200 mm 3 for KYSE150, mice were given an initial dose of HXR9 of 100 mg/kg (i.v. or injected directly into tumors), followed by twice weekly treatments at 10 mg/kg. Tumor volume was measured every 2-3 days. Tumor growth curves indicated that HXR9 slowed down tumor growth significantly compared to CXR9, and mice given HXR9 showed significant tumor volume reduction from day 6. However, the HXR9-treated mice did not suffer greater weight loss. ***P < 0.05
( Figure 3C ). To investigate whether HXR9 triggers apoptosis in vivo, we detected the expression of Caspase-3, PARP and c-fos in tumors removed from xenograft models, and found that they were remarkably upregulated in HXR9-treated tumors ( Figure 3D ).
| HXR9 causes transcription alteration
HXR9 is considered a specific, competitive inhibitor of HOX/PBX interaction by mimicking the "hexapeptide" sequence of HOX F I G U R E 3 HXR9 induced esophageal squamous cell carcinoma cell apoptosis. A, Effect of HXR9 or CXR9 on cell apoptosis was assessed by flow cytometry using Annexin V/PE after treatment for 2 h. The apoptosis rate for HXR9-treated cells was significantly higher than that for CXR9-treated cells. 
| D ISCUSS I ON
Previously, HOXB7, HOXC6 and HOXC8 were found to be dysregulated in ESCC tissues. To elucidate their significance in ESCC, it is necessary to clarify the association between their expression patterns and patient prognosis. It was shown that the survival time of patients with high HOXB7 or HOXC6 or HOXC8 expression was significantly shorter than that of patients with low expression, which is similar to the results of other groups.
27-29
As reported, the consequences of dysregulated HOX genes in carcinogenesis can be interpreted as an extension of their normal function. [30] [31] [32] Given that HOX genes can be viewed as global regulators of growth and differentiation, we investigated whether they could modulate the malignant phenotype in esophageal cancer. To this end, we established stable knockdown cell culture models by using RNAi, and explored their effect which was previously shown to cause apoptosis and inhibit tumor survival in a variety of tumor types, [23] [24] [25] [26] implying that the HOX/ PBX interaction is a potential target for therapy. In the present study, we also showed that treating ESCC cells with HXR9 caused apoptosis and inhibited cell proliferation and tumor growth in all of the lines tested. It has been reported that a rapid increase in c-fos expression as a response to HOX/PBX inhibition was activated to induce apoptosis, [23] [24] [25] 33 which was also confirmed in our study. In addition, we found that PI3K-AKT and JAK-STAT pathway repression may be a response to antiproliferation and proapoptosis. Previously, it was reported that HOXB7 was possibly involved in regulating the downstream PI3K/AKT pathway in a study identifying potential chromatin binding sites of HOXB7. 
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